Eterna hosts inaugural meeting of newly formed SAB

Eterna (ERNA) Therapeutics announced a successful inaugural meeting of its newly formed Scientific Advisory Board, SAB. The meeting brought together leading experts in cell therapy to evaluate preclinical advances, address key scientific questions, refine the company’s research and development priorities, and discuss the roadmap to human clinical trials. The board consists of leaders in the field, including: Michael Andreeff; Christopher Rohde; Blythe Sather; Jerome B. Zeldis